Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Transplant Drug Stimulates Immune Memory
Rapamycin, a drug given to transplant recipients to suppress their immune systems, has a paradoxical effect on cells responsible for immune memory, scientists at the Emory Vaccine Center have discovered.
generic viagra online
California Group To Boost HIV Prevention Measures In Adult Film Industry
The California-based clinic Adult Industry Medical Healthcare Foundation (AIMHF), which serves the adult film industry, said on Monday it will boost its HIV prevention measures by urging the industry to use an online database to verify that employees have recently been tested for HIV, the Los Angeles Times reports. The industry currently requires that workers be tested every 30 days. Los Angeles County health officials recently reported that there had been 16 unpublicized cases of HIV in adult film workers in the county since 2004 after news emerged last week that an adult film actress tested positive for HIV (Yoshino, Los Angels Times, 6/15).
News of the day
Reduced Risk Of Stroke, Further Heart Attack And Death For Patients After A Heart Attack Or Unstable Angina With Oral Rivaroxaban
The findings of the ATLAS ACS-TIMI 46 study are reported in an article Online First and in a future edition of The Lancet, and written by Dr Jessica L Mega, Brigham and Women"s Hospital, Boston, MA, USA, and collaborators. They suggest that the intake of the oral anti-clotting drug rivaroxaban in patients after an acute coronary syndrome (such as a heart attack or an unstable angina) reduces the risk of stroke, another heart attack, and death.
Medical Devices

New York Times Examines Debate Surrounding Use Of Experimental Treatments In Terminally Ill Patients

Some patient advocates are lobbying to legalize "compassionate use" of experimental drugs for people with terminal illnesses who have exhausted other treatments, prompting a debate about how and when to provide such patients with treatments that could prolong their lives, the New York Times reports. Most insurers do not cover unproven treatments, and physicians have concerns that using experimental treatment could give patients false hope and cause unnecessary pain. Drugmakers are concerned that if there are unfavorable outcomes from providing patients with an unproven treatment, it could hurt the drug"s chances of receiving FDA approval. At the same time, FDA does not want to grant drugs and their makers the opportunity to skip clinical trials. Currently, patients must individually apply to receive treatments through compassionate use (Harmon, New York Times, 5/17). Reprinted with kind permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation. © 2009 Advisory Board Company and Kaiser Family Foundation. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009